Enteris BioPharma offers innovative formulation solutions built around its proprietary oral drug delivery technology platform – Peptelligence®. Since its founding in 2013, Enteris BioPharma has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective to enable the delivery of peptide-based therapeutics and other molecules with low oral bioavailability. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square-foot GMP facility in Boonton, New Jersey, offering a range of manufacturing services. Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH). SWK offers Enteris with sound financial backing and long range planning support.
Enteris BioPharma is an independent, wholly-owned subsidiary of SWK Holdings Corporation, a publically traded company (Nasdaq: SWKH) and offers innovative formulation solutions and manufacturing services. Enteris has access to capital and resources that it can direct towards expansion and growth opportunities.